Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens.
What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of years of persistence by an extraordinary team of scientists, engineers, clinical advisors, and partners who refused to let go of a vision to transform human sight.
This is more than a milestone; it is a turning point for ophthalmology and for millions of people worldwide who are waiting for new solutions. And while we celebrate this historic success, we know our mission is far from complete. With more determination than ever, we move forward to deliver the Ocumetics Lens to patients everywhere and reshape the future of vision.
Best regards
Dean Burns
President, CEO and Director
Ocumetics Technology
Calgary, AB – TheNewswire – January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it has closed the first tranche of its previously announced best efforts brokered private placement of units of the Company (the “Units”) for aggregate gross proceeds of approximately
Calgary, AB – TheNewswire – December 19, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) announces that further to its previously announced (November 25, 2025) brokered private placement (the “Offering”) on a best-efforts basis led by Centurion One Capital Corp. (the “Lead Agent”), the Corporation has amended the
Calgary, Alberta – TheNewswire – December 9, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to
